Member Info for Morgank

It’s nothing more than other companies are doing, but because it’s SEE it has to be a dog of a company. If ppl have sold out why are they still here posting , I question ?

A reduction of A$12 mil costs over 2020/21 , hope the market takes it well

See RNS

Use the filter ! This board is clogged up with ping pong that’s serving no purpose

https://mobile.reuters.com/article/amp/idUSKBN22R2D0?__twitter_impression=true

https://twitter.com/semicast_res/status/1261205305666535424?s=20

Welcome ‘Sport’, any post relative to SEE is welcome good or bad as long as it has fact to back it up not just ludicrous in factual comments.
The whole idea of this board is to bring together information relevant to this company to give the broadest view to anyone interested in investing or those invested .
The difficulty with this company in the verticals they are operating is NDA’s so much investigation goes on to work out who might be involved in contracts won.
All I would say is if your interested read what’s here but please don’t criticise information that might be of relevance to others
DYOR GLA

See today’s RNS

https://www.tradingview.com/chart/SEE/x5cw96VE-Seeing-Machines-next-roadmap-Long/

My favourite stock is SEE:LSE I believe we are in a wave 3 start at the moment to top for end of MAY 2020 targeting higher as a crucial pivot point . Clear falling wedge formed as part of sub w2 of larger w3. Significantly undervalued share price needs to turn back where it belongs to. Market potential here is massive for 2020-2021 and in the mid and long term. Buy the rumours.

SP Started off heading down as usual On selling then some reasonable buying bringing the SP back to unchanged.
A long period of very little trading, the bid moves up with some more selling to leave SP positive for the day.
Seems a delayed trade published after the close moved the bid.
Glad of the change of direction

https://www.primemovermag.com.au/news/article/hi-trans-goes-all-in-on-seeing-machines-in-cab-tech

Now 66, I expected a small rise but not a fall, usually more interest from the US, so maybe hope later.

This machine has so much to offer, it’s a shame it’s held back by Covid

Angle PLC CTC potential as biomarker in MET inhibitor trials

Source: RNS Non-Regulatory
TIDMAGL

Angle PLC

12 May 2020


For immediate release 12 May 2020

ANGLE plc ("the Company")

MET EXPRESSION OF PARSORTIX-HARVESTED CTCs FROM CANCER PATIENTS HAS POTENTIAL AS BIOMARKER FOR MET INHIBITOR DRUG TRIALS

Potential for liquid biopsy solution to drive new areas of cancer treatment

Parsortix performance demonstrates key advantages over alternative approaches

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that the Liquid Biopsy Analysis Unit at the Health Research Institute of Santiago, Spain has published results of new work undertaken in head and neck cancer and non small cell lung cancer on the potential utility of a liquid biopsy-based strategy to assess MET alterations on circulating tumour cells (CTCs).

MET alterations in cancer patients may provide a biomarker to evaluate which patients will benefit from treatment with a new class of drug called MET inhibitors. The MET-related cancer pathways can activate cell proliferation, survival, migration, motility, invasion, angiogenesis, apoptosis and epithelial-to-mesenchymal transition. Thus, the MET pathways have a fundamental bearing on the rate of growth and spread of cancer.

MET changes have mostly been associated with metastatic patients and normally appear with progression of the cancer. Consequently the original tissue biopsy may be out-of-date and unreliable for assessing the current MET status. Repeat tissue biopsies may not be possible if the metastatic site cannot be accessed, the patient is too ill for the invasive procedure or there is insufficient tissue available for biopsy analysis. The researchers are the first to investigate the use of liquid biopsy systems to capture CTCs in order to investigate MET expression levels in the cancer, in a study comparing the utility of Parsortix to that of the leading antibody-based CTC system.

The head and neck cancer results using Parsortix showed a significant association of the presence of MET positive CTCs, which was a minority of patients, and poorer overall survival of those patients. For comparative purposes, the leading antibody-based CTC system was utilised in parallel with the same patients. This system had significantly lower CTC positivity than Parsortix and there was no relationship between MET expression in the CTCs obtained by the antibody-based system with patient survival.

This research suggests that there is potential for the Parsortix system to be used as part of a biomarker approach in cancer drug trials of MET inhibitors, and then potentially as a companion diagnostic to identify patients likely to respond to the MET inhibitor drugs. The paper entitled "Detection of MET Alterations Using Cell Free DNA and Circulating Tumor Cells from Cancer Patients" has been published in the peer-reviewed journal Cells and can be accessed via https://angl

Finally executed @2.65 not we are on the rise again

Still waiting for a 100k buy order to be filled, 20 mins now, but can sell immediately 100k, are they trying to fill a large buy order ?

Can’t get a quote to buy 100k

The Car Is Staging a Comeback, Spurring Oil’s Recovery .
Only 10% of original capacity on public transport due to Covid social distancing.
Staycations will increase car travel as international travel in doubt for some while

Good to see Guardian no’s increasing , still time to meet y/e targets especially with the insurance promotions

3 attempts @ this recently, let’s hope 3 holds

See if it recovers like yesterday